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Key Clinical Message
An isolated IgA-mediated autoimmune hemolytic anemia can present a diag-
nostic challenge. When a routine direct antiglobulin test (DAT) is negative but
clinical suspicion remains high, further testing with monospecific antisera
should be performed. As with IgG-mediated WAIHA, steroids are first-line
treatment, though splenectomy is often required to achieve a durable treatment
response.
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Introduction
A 77-year-old Caucasian female was transferred from a
referring hospital to the inpatient medical floor for evalu-
ation of refractory hemolytic anemia. The patient initially
reported several days of fatigue, jaundice, and darkening
of her urine, approximately 1 month prior to her current
presentation. At the referring hospital, she was found to
have hemolytic anemia, thrombocytopenia, and acute kid-
ney injury. She was first thought to have thrombotic
thrombocytopenic purpura and plasmapheresis was
implemented. It subsequently was discontinued when the
ADAMSTS13 level came back as normal. On review of
her peripheral blood smear, spherocytes were noted and a
diagnosis of autoimmune hemolytic anemia was made,
despite a negative Coombs test. The patient was started
on corticosteroids and weekly rituximab. She was dis-
charged after a several week admission on a steroid taper
and with a plan for her to complete four weekly doses of
rituximab.
Within a few days after discharge, however, her fatigue
and jaundice recurred. She was noted to have blood in
her urine by a visiting nurse. She was again admitted to
the referring hospital where she was found to have wors-
ening of her anemia and thrombocytopenia. She received
three doses of IVIG, with subsequent improvement of her
hemoglobin and platelet levels. Her labs revealed ongoing
hemolysis, however, and a splenectomy was recom-
mended. She then requested transfer to our institution
for a second opinion.
The patient’s initial presentation with fatigue, jaundice
and dark urine is concerning for anemia secondary to a
hemolytic process. A microangiopathic process, including
thrombotic thrombocytopenic purpura, hemolytic uremic
syndrome, and disseminated intravascular coagulation,
should be considered. Autoimmune hemolytic anemia
(AIHA) can be idiopathic or secondary to many disease
processes, including infection, rheumatologic conditions,
drug exposure, and lymphoproliferative disorders. Parox-
ysmal nocturnal hemoglobinuria presents with hemolytic
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anemia, although it is also associated with thrombosis
and pancytopenia. Other causes of Coomb’s negative
hemolytic anemia include hereditary spherocytosis, RBC
enzymopathy, and Wilson’s disease.
Case History
The patient complained of significant fatigue and dyspnea
on exertion. She also reported night sweats throughout
the month prior to her presentation. The patient had a
15 lb. weight loss over the course of a few months and
was prescribed an appetite stimulant. She denied any
recent history of infection. The patient had no joint com-
plaints. Her past medical history was significant for colo-
rectal cancer, which was diagnosed 9 years ago and
treated with surgical resection, chemotherapy, and radia-
tion. She also had a history of idiopathic thrombocytope-
nic purpura (ITP) approximately two decades prior to
her current presentation. She was treated with steroids
which resulted in normalization of her platelet count.
Since her diagnosis of ITP, she had been followed by a
hematologist regularly. The patient’s home medications
included amlodipine, levothyroxine, vitamin D3, albu-
terol, mirtazapine, atenolol-chlorthalidone, raloxifene,
lisonopril, furosemide, and potassium supplementation.
Her family history was notable for pancreatic cancer in
her mother. She lived with her husband and was retired.
On examination, she appeared pale and fatigued, but
she was in no acute distress. Her temperature was 36.9°C,
pulse 69, respiratory rate 22, blood pressure 135/64 mm
Hg, and oxygen saturation 94% on 4 L nasal cannula.
The patient had scleral icterus and trace peripheral
edema. She had no splenomegaly, lymphadenopathy,
petechiae, or purpura on examination.
Differential Diagnosis
Given the patient’s age, history of carcinoma, and prior
episode of ITP, a secondary AIHA due to an underlying
malignancy or rheumatologic condition, is possible. Sec-
ondary causes of AIHA are determined in 20–80% of
cases, depending on the patient population being studied
[1]. Lymphoproliferative disorders, including chronic
lymphocytic leukemia (CLL), Hodgkin’s disease, non-
Hodgkin’s lymphoma, and Waldenstr€om’s macroglobulin-
emia, are the most common causes of secondary cases of
warm antibody autoimmune hemolytic anemia (WAIHA)
[1]. The patient’s history of malignancy and recent weight
loss raises suspicion for recurrence. In the setting of solid
tumors, both a warm or cold antibody autoimmune
hemolytic anemia (CAIHA) are possible, though warm
antibodies are more common [2]. Review of patient’s
medication list revealed no clear source for a drug-
induced immune hemolytic anemia (DIIHA). Medications
most commonly associated with DIIHA include ceftriax-
one, piperacillin, and cefotetan [3].
Laboratory and Imaging Evaluation
The patient’s white blood cell count was 16,100 per cubic
millimeter, with 96.7% neutrophils, 0.3% lymphocytes,
1.0% monocytes, 0% eosinophils, 0.3% basophils, and
1.7% immature granulocytes. The hemoglobin level was 7.5
g per deciliter, with a mean corpuscular volume of 100.9 fL.
At the referring hospital her hemoglobin was 6.4 g per
deciliter for 2 days prior to transfer despite transfusion of 6
units of packed red blood cells. The platelet count was
145,000 per cubic millimeter. The prothrombin time
and partial thromboplastin time were both normal. The
serum sodium, potassium, and bicarbonate were all within
normal limits. The serum creatinine was 0.8 mg per decili-
ter and the blood urea nitrogen was 36 mg per deciliter.
The patient’s liver enzymes were normal. The bilirubin was
1.9 mg per deciliter. LDH was 940 (normal range 120–240)
and haptoglobin was <10 mg per deciliter.
The peripheral blood smear revealed >5 spherocytes
per high-power field. Schistocytes were not identified.
White blood cell number and morphology were normal.
Flow cytometry was sent to evaluate for paroxysmal noc-
turnal hemoglobinuria (PNH) and cold agglutinin titers
were obtained.
The decreased haptoglobin, elevated LDH, and reticulo-
cytosis, are all consistent with hemolytic anemia. A mi-
croangiopathic process is unlikely given the lack of
schistocytes. The spherocytes seen on peripheral blood
smear could be consistent with hemolytic anemia or sec-
ondary to recent transfusion at the referring hospital. In
order to further investigate potential secondary causes of
AIHA, including lymphoma, solid tumors, and clonal im-
munoglobulins, a computed tomographic (CT) scan and
bone marrow evaluation should be obtained.
A CT scan of the chest, abdomen, and pelvis was
obtained and revealed fluid within the endometrial canal.
There were no enlarged abdominal, retroperitoneal, or
pelvic lymph nodes. In the chest, there were small to
moderate layering right and small left pleural effusions.
Flow cytometry revealed no evidence of a PNH clone.
ADAMTS13 activity returned at 47%. Cold agglutinins
were <1:10. Bone marrow biopsy from the referring hos-
pital was reviewed and exhibited a normocellular marrow
with erythroid hyperplasia and stress dyserythropoiesis.
There was no evidence of neoplasia. Direct antiglobulin
test (DAT) returned negative for IgG and C3.
The patient was continued on prednisone 50 mg daily
and transfused two units of packed red blood cells. Ritux-
imab was held while further evaluation was completed.
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She initially responded appropriately to the transfusion
with her hemoglobin increasing from 7.0 to 10.4 g per
deciliter. Within 3 days, her hemoglobin had decreased to
8.8 g per deciliter.
Given the finding of fluid within the endometrial canal
on CT scan, a gynecologist was consulted and a transva-
ginal ultrasound was obtained. Ultrasound revealed multi-
ple endometrial masses and moderate pelvic ascites.
Despite a negative DAT, there was still strong suspicion
for an AIHA. Further testing is required in such cases in
order to determine the pathogenic autoantibody and to
confirm the diagnosis. The DAT is a screening test and
only detects the presence of IgG and/or complement (C3)
on the surface of erythrocytes [4]. If the initial screen is
positive with a negative albumin control, then testing
with monospecific antisera (anti-IgG, anti-C3d) is per-
formed [5]. Approximately 1–10% of patients diagnosed
with AIHA have been reported to have a negative DAT
[6]. Few of the DAT negative cases of AIHA are due to
IgA autoantibodies, which are not detected with typically
available antisera. At this time, there are no FDA-
approved anti-IgA (or anti-IgM) reagents for use in
patient transfusion testing. These cases must be sent to a
handful of outside immunohematology reference labora-
tories, using unlicensed reagents.
Direct antiglobulin test polyspecific interpretation was
positive 1+ and a warm autoantibody was detected. Test-
ing at the LA American Red Cross laboratory performed
with an anti-IgA reagent revealed strong reactivity (3+)
and confirmed the presence of an IgA autoantibody.
Treatment and Follow-up
The patient’s hemoglobin decreased to 6.7 g per deciliter
4 days after transfusion with 2 units packed red blood
cells. She received a fourth dose of Rituximab and was
transfused once again with 2 units of PRBCs. Her hemo-
globin increased appropriately to 9.2 g per deciliter.
The patient developed gross hematuria with a foley
catheter in place. The Foley catheter was initially placed
at the referring hospital due to episodes of acute urinary
retention. Urology was consulted and upon irrigation,
there were several blood clots removed. She ultimately
underwent cystoscopy and hysteroscopy which revealed
radiation changes of the urothelium and benign endome-
trial polyps.
One week after her second transfusion, the patient’s
hemoglobin decreased to 7.7 g per deciliter. Her ongoing
anemia was thought to mainly be secondary to the hema-
turia and not due to ongoing hemolysis. LDH decreased
to 342, down from 940 at admission. She was continued
on prednisone 40 mg daily with a plan for a 3-month
long taper. If she relapsed while on steroid therapy, it was
discussed with the patient that she would be referred for
splenectomy. The patient completed the steroid taper
under the supervision of her local hematologist, without
evidence of relapse as per our last communication.
Initial treatment of WAIHA is with glucocorticoids.
Typically, 15–20% of patients will have complete remission
and be able to discontinue steroids, however, most patients
will require maintenance dosing [1]. Steroid refractoriness
is often seen in patients with underlying malignant tumors,
benign ovarian teratomas, or with warm IgM antibodies
[1]. In case reports of IgA-AIHA, patients have been
responsive to steroids at least initially, but there are several
reports of splenectomy ultimately being required [7, 8].
After splenectomy, steroid therapy was able to be discon-
tinued in each case [7, 8]. In patients who have contraindi-
cations to splenectomy or decline surgery, rituximab is
another second-line treatment option [9]. In a retrospec-
tive study of 11 patients with primary WAIHA treated with
rituximab, eight patients had a complete response and
three patients had a partial response [10].
Discussion
The majority of AIHA cases are caused by warm antibodies,
with IgG being the most commonly involved. IgA antibod-
ies in the context of WAIHA are rare, occurring alone or
with complement in <2% of patients, thus routine screen-
ing with serum containing anti-IgG and anti-C3d is diag-
nostic in most cases of WAIHA [7]. An analysis including
5,177 patients with AIHA included only 5 cases (<0.1%)
due to autoantibodies which were exclusively of the IgA is-
otype [11]. Case reports of IgA-mediated WAIHA include
an infant, a woman with superficial thrombophlebitis, a
patient with Hodgkin lymphoma, and a patient with a his-
tory of renal transplant [4, 7, 9, 12].
The pathogenesis of IgA-mediated hemolysis was
revealed through the identification of specific Fc receptors
for IgA on lymphocytes, granulocytes, and monocytes [13].
IgA autoantibodies cause hemolysis by adherence of anti-
body-coated erythrocytes to Fc receptors of phagocytic cells
[13]. There has also been suggestion of the activation of
complement by IgA autoantibodies leading to a C3 coating
of erythrocytes with subsequent-enhanced trapping by
macrophages [4]. Thus, both complement-independent
and complement-mediated processes are thought to be
involved in the pathogenesis of IgA-mediated AIHA.
An isolated IgA-mediated AIHA is a rare clinical entity.
When a routine DAT is negative but clinical suspicion
remains high for AIHA, further testing with monospecific
antisera should be performed. As with IgG-mediated
WAIHA, steroids are first-line treatment, though splenec-
tomy is often required to achieve a durable treatment
response.
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